サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
市場調査レポート
商品コード
1424131

ワクチンアジュバント市場規模・予測、世界・地域シェア、動向、成長機会分析レポート対象範囲：アジュバントクラス別、タイプ別、地域別

Vaccine Adjuvant Market Size and Forecast, Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Adjuvant Class, Type, and Geography
出版日: | 発行: The Insight Partners | ページ情報: 英文 155 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.53円
ワクチンアジュバント市場規模・予測、世界・地域シェア、動向、成長機会分析レポート対象範囲：アジュバントクラス別、タイプ別、地域別
出版日: 2024年01月09日
発行: The Insight Partners
ページ情報: 英文 155 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 図表
  • 目次
概要

ワクチンアジュバント市場は、2022年の24億8,200万米ドルから2028年には69億3,100万米ドルに成長すると予想され、2022年から2028年までのCAGRは13.7%と予測されています。アジュバント研究の開発や製品上市のための共同作業への支援は、ワクチンアジュバント市場に機会を創出し、ワクチンアジュバント市場の成長を牽引する影響力のある市場成長の単独要因となっています。

アジュバントはワクチン製剤に添加される成分であり、ワクチンを接種する人々に強い免疫反応を起こさせる。感染症の発生やパンデミックの増加、動物用ワクチンアジュバントの規制当局による承認は、市場開拓を推進する主な要因です。しかし、製品の回収や副作用がワクチンアジュバント市場の成長を妨げています。

成長の促進要因

アジュバント研究の市場開拓支援と製品上市に向けた共同努力がワクチンアジュバント市場にチャンスをもたらす

国立アレルギー・感染症研究所（NIAID）は、新しいワクチンアジュバントの開発、発見、特性評価に重要な役割を果たしています。同研究所は、現行のワクチンの有効性を向上させ、既存および新興感染症に対する新規またはより優れたワクチンを設計し、アレルギー、自己免疫疾患、がんを治療するワクチンを開発する上で重要な役割を果たしています。さらに、NIAIDのワクチンアジュバント研究プログラムは、最終的なワクチンの有効性を最適化するために抗原と適合させることができる候補を含む一連のアジュバントを開発することを目的としています。そのため、NIAIDが支援するワクチンアジュバント研究者と、より広範な科学コミュニティとの連携を促進するため、NIAIDは2020年にワクチンアジュバントコンペンディウム（VAC）を設立しました。このウェブベースのツールはアジュバントの特性を表示し、ワクチン開発者が対象疾患に適したアジュバントを特定するのに役立ちます。

SKバイオサイエンシズやGSKのようなワクチン事業を展開する企業は、提携などの成長戦略を実施することで、世界の需要に対応するアジュバントを大規模に生産しています。例えば、SKバイオサイエンシズとGSKは2022年4月、第3相臨床試験で得られた良好なデータを受け、韓国食品医薬品安全部（KMFDS）にSKYCovioneの生物学的製剤許可申請を提出したと発表しました。したがって、ワクチンアジュバントの研究開発を促進するために様々な政府当局から提供される支援、トップメーカー間の協力、およびこのような協力的な事業戦略による革新的な製品の発売は、予測期間中にワクチンアジュバント市場の成長に有利な機会を提供すると考えられます。

2022年のアジュバントクラス別ワクチンアジュバント市場では、鉱塩アジュバントセグメントが最大のシェアを占めました。エマルジョンアジュバントセグメントの市場は、予測期間中に14.6%という最も速いCAGRで成長すると予測されています。不溶性アルミニウム塩やリン酸カルシウムなどのミネラル塩は、ワクチン製剤のアジュバントとして使用されます。アルミニウム塩ベースのアジュバントは、早期かつ長期にわたる防御免疫の誘導に役立ちます。ヒト用ワクチンに使用されるアルミニウムアジュバントは米国食品医薬品局（FDA）により規制されており、少量のアルミニウムが添加されることで、ワクチン中の抗原単独よりも高い免疫原性が体内に構築されます。炎症部位へのミネラル塩アジュバント製剤は、炎症性サイトカインを放出することにより、迅速な免疫反応を引き起こします。したがって、鉱物塩ベースのアジュバントが抗原に対する迅速な免疫反応を誘導する能力は、ワクチンアジュバント市場の成長に有利です。

2022年には、北米がワクチンアジュバントの世界市場シェアで最大を占めました。アジア太平洋地域は2022年から2030年にかけて最も高いCAGRを記録すると予想されています。ワクチンアジュバントの製品承認が加速し、北米の市場成長を後押しします。さらに、アジュバントを生産するトップメーカーの存在が市場全体の成長をさらに後押ししています。

迅速な製品承認プロセスが米国のワクチンアジュバント市場に利益をもたらしています。2023年5月、グラクソ・スミスクライン（GSK）は、呼吸器合胞体ウイルス（RSV）による下気道疾患（LRTD）の予防を目的としたArexvy（呼吸器合胞体ウイルスワクチン、アジュバント）ワクチンの米国食品医薬品局（FDA）承認を獲得しました。このため、AREXVYはFDAが承認した世界初の高齢者向けRSVワクチンとなった。2022年10月、Novavax, Inc.はCOVID-19アジュバントワクチンの緊急使用許可（EUA）をFDAから取得しました。

業界の動向と将来の機会：

ワクチンアジュバント市場で事業を展開する大手企業による様々な戦略的開拓を以下に示す：

2022年4月、GSK plcとSK Bioscienceは、組み換えタンパク質ベースのアジュバント付きCOVID-19ワクチン候補であるSKYCovioneの生物製剤承認申請を行った。このワクチンにはGSKのパンデミック・アジュバントが含まれています。両社は第III相臨床試験で得られた良好なデータを受け、韓国食品医薬品安全部に生物製剤承認申請を提出しました。

セピック社は2021年11月、鳥類注射用ワクチン専用の高分子技術に基づく水性アジュバント「MONTANIDE GEL P PR」を上市し、鳥類市場における無害化のニーズに応えています。また、MONTANIDE GEL P PRは特に安定性が高く、鳥類ワクチンで頻繁に使用される不安定な抗原培地に耐えることができます。

2023年10月、SPIファーマとQ-Vant Biosciences Inc.は、Q-Vantの持続可能なサポニン抽出技術におけるリーダーシップと、SPIの製薬業界における世界なリーチとサービスの専門知識を組み合わせた提携を発表しました。この提携には、Q-Vant社独自の100％持続可能なQ-SAP技術の拡大への投資と、動物用およびヒト用ワクチン製剤へのサポニンアジュバントの世界の採用を加速するための独占的商業契約が含まれます。

2023年1月、韓国食品医薬品安全部（KMFDS）はSKバイオサイエンスに対し、18歳以上の成人にブースターとして投与するNuvaxovidTMの製造販売承認を強化しました。

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

  • 主要な洞察

第3章 調査手法

  • 調査範囲
  • 2次調査
  • 1次調査

第4章 ワクチンアジュバントの市場情勢

  • PEST分析

第5章 ワクチンアジュバント市場- 主要市場力学

  • ワクチンアジュバント市場：主要市場力学
  • 市場促進要因
    • 感染症発生数の増加とパンデミック
    • 動物用ワクチンアジュバントの承認
  • 市場抑制要因
    • 製品回収と副作用
  • 市場機会
    • アジュバント研究開発への支援と製品上市に向けた共同努力
  • 今後の動向
    • 技術の進歩
  • 促進要因と抑制要因の影響

第6章 ワクチンアジュバント市場：世界市場分析

  • ワクチンアジュバント市場の収益、2022-2030年
  • ワクチンアジュバント市場-2030年までの収益と予測

第7章 ワクチン用アジュバント市場分析：アジュバントクラス別

  • ミネラル塩アジュバント
  • エマルジョンアジュバント
  • リポソームアジュバント
  • その他

第8章 ワクチンアジュバントの市場分析：タイプ別

  • ヒト用ワクチンアジュバント
  • 動物用ワクチンアジュバント

第9章 ワクチンアジュバント市場：地域別分析

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他欧州
  • アジア太平洋
    • 中国
    • 日本
    • インド
    • オーストラリア
    • 韓国
    • APACのその他諸国
  • 中東・アフリカ
    • サウジアラビア
    • 南アフリカ
    • アラブ首長国連邦
    • その他中東とアフリカ
  • 中南米
    • ブラジル
    • アルゼンチン
    • その他中南米

第10章 業界情勢

  • 世界のワクチンアジュバント市場における成長戦略
  • オーガニック開発
  • 無機的展開

第11章 企業プロファイル

  • SPI Pharma Inc
  • GSK Plc
  • CSL Ltd
  • Seppic SA
  • Hawaii Biotech Inc
  • Dynavax Technologies Corp
  • InvivoGen SAS
  • Croda International Plc
  • Novavax Inc
  • Phibro Animal Health Corp

第12章 付録

図表

List Of Tables

  • Table 1. Vaccine Adjuvants Market Segmentation
  • Table 2. North America: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Adjuvant Class
  • Table 3. North America: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 4. United States: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Adjuvant Class
  • Table 5. United States: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 6. Canada: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Adjuvant Class
  • Table 7. Canada: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 8. Mexico: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Adjuvant Class
  • Table 9. Mexico: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 10. Europe: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Adjuvant Class
  • Table 11. Europe: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 12. Germany: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Adjuvant Class
  • Table 13. Germany: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 14. United Kingdom: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Adjuvant Class
  • Table 15. United Kingdom: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 16. France: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Adjuvant Class
  • Table 17. France: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 18. Italy: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Adjuvant Class
  • Table 19. Italy: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 20. Spain: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Adjuvant Class
  • Table 21. Spain: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 22. Rest of Europe: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Adjuvant Class
  • Table 23. Rest of Europe: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 24. Asia Pacific: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Adjuvant Class
  • Table 25. Asia Pacific: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 26. China: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Adjuvant Class
  • Table 27. China: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 28. Japan: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Adjuvant Class
  • Table 29. Japan: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 30. India: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Adjuvant Class
  • Table 31. India: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 32. Australia: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Adjuvant Class
  • Table 33. Australia: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 34. South Korea: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Adjuvant Class
  • Table 35. South Korea: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 36. Rest of APAC: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Adjuvant Class
  • Table 37. Rest of APAC: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 38. Middle East and Africa: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Adjuvant Class
  • Table 39. Middle East and Africa: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 40. Saudi Arabia: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Adjuvant Class
  • Table 41. Saudi Arabia: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 42. South Africa: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Adjuvant Class
  • Table 43. South Africa: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 44. United Arab Emirates: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Adjuvant Class
  • Table 45. United Arab Emirates: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 46. Rest of Middle East and Africa: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Adjuvant Class
  • Table 47. Rest of Middle East and Africa: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 48. South and Central America: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Adjuvant Class
  • Table 49. South and Central America: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 50. Brazil: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Adjuvant Class
  • Table 51. Brazil: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 52. Argentina: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Adjuvant Class
  • Table 53. Argentina: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 54. Rest of South and Central America: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Adjuvant Class
  • Table 55. Rest of South and Central America: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 56. Organic Developments Done by Companies
  • Table 57. Inorganic Developments Done by Companies
  • Table 58. Glossary of Terms, Vaccine Adjuvants Market

List Of Figures

  • Figure 1. Vaccine Adjuvants Market Segmentation, by Geography
  • Figure 2. PEST Analysis
  • Figure 3. Impact Analysis of Drivers and Restraints
  • Figure 4. Vaccine Adjuvants Market Revenue (US$ Million), 2022-2030
  • Figure 5. Vaccines Adjuvants Market, By Geography Forecast Analysis, 2022 & 2030
  • Figure 6. Vaccine Adjuvants Market Share (%) - by Adjuvant Class (2022 and 2030)
  • Figure 7. Mineral Salt Adjuvant: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 8. Emulsion Adjuvant: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 9. Liposome Adjuvant: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 10. Others: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 11. Vaccine Adjuvants Market Share (%) - by Type (2022 and 2030)
  • Figure 12. Human Vaccine Adjuvant: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 13. Veterinary Vaccine Adjuvant: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 14. North America: Vaccine Adjuvants Market by Key Countries - Revenue (2022) US$ Million
  • Figure 15. North America Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 16. North America: Vaccine Adjuvants Market Breakdown, by Key Countries, 2022 and 2030 (%)
  • Figure 17. United States: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 18. Canada: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 19. Mexico: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 20. Europe: Vaccine Adjuvants Market - Revenue by Key Countries Revenue 2022 (US$ Million)
  • Figure 21. Europe Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 22. Europe: Vaccine Adjuvants Market (2022 and 2030)
  • Figure 23. Germany: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 24. United Kingdom: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 25. France: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 26. Italy: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 27. Spain: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 28. Rest of Europe: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 29. Asia Pacific: Vaccine Adjuvants Market - Revenue by Key Countries 2022 (US$ Million)
  • Figure 30. Asia Pacific: Vaccine Adjuvants Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 31. Asia Pacific: Vaccine Adjuvants Market Breakdown, by Key Countries, 2022 and 2030 (%)
  • Figure 32. China: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 33. Japan: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 34. India: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 35. Australia: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 36. South Korea: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 37. Rest of APAC: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 38. Middle East and Africa: Vaccine Adjuvants Market by Key Countries - Revenue 2022 (US$ Million)
  • Figure 39. Middle East and Africa: Vaccine Adjuvants Market Revenue and Forecast to 2030 (US$ Million)
  • Figure 40. Middle East and Africa: Vaccine Adjuvants Market Breakdown, by Key Countries, 2022 and 2030 (%)
  • Figure 41. Saudi Arabia: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 42. South Africa: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 43. United Arab Emirates: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 44. Rest of Middle East and Africa: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 45. South and Central America: Vaccine Adjuvants Market by Key Countries - Revenue 2022 (US$ Million)
  • Figure 46. South and Central America: Vaccine Adjuvants Market, Revenue and Forecast to 2030 (US$ Million)
  • Figure 47. South and Central America: Vaccine Adjuvants Market Breakdown, by Key Countries, 2022 and 2030 (%)
  • Figure 48. Brazil: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 49. Argentina: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 50. Rest of South and Central America: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 51. Growth Strategies in the Global Vaccine Adjuvants Market
目次
Product Code: TIPRE00004430

The vaccine adjuvants market is expected to grow from US$ 2.482 billion in 2022 to US$ 6.931 billion by 2028; it is expected to grow at a CAGR of 13.7% from 2022 to 2028. Support for developments in adjuvant studies and collaborative efforts for product launches creates opportunities for the vaccine adjuvant market, a standalone factor responsible for influential market growth driving the vaccine adjuvants market growth.

An adjuvant is a component added to vaccine preparations to create a stronger immune response in people receiving the vaccine. The rising occurrence of infectious disease outbreaks and pandemics and regulatory approvals of veterinary vaccine adjuvants are the key factors propelling the market development. However, product recall and adverse effects hamper the vaccine adjuvant market growth.

Growth Drivers:

Support for Developments in Adjuvant Studies and Collaborative Efforts for Product Launches Creates Opportunities for Vaccine Adjuvant Market

The National Institute of Allergy and Infectious Disease (NIAID) plays an important role in developing, discovering, and characterizing new vaccine adjuvants. The institute plays a crucial role in improving the efficacy of current vaccines, designing new or better vaccines against existing and emerging infectious diseases, and developing vaccines to treat allergies, autoimmune diseases, and cancer. Additionally, NIAID's vaccine adjuvant research program aims to develop a set of adjuvants, including candidates that can be matched with antigens to optimize the final vaccine efficacy. Therefore, to foster the collaboration between NIAID-supported vaccine adjuvant researchers and a broader scientific community, NIAID established the Vaccine Adjuvant Compendium (VAC) in 2020. This web-based tool displays adjuvant characteristics to help vaccine developers identify adjuvants suitable for their target disease.

Companies in the vaccine business, such as SK Biosciences and GSK, are producing adjuvants on a large scale to meet global demand by implementing growth strategies such as collaborations. For instance, in April 2022, SK Biosciences and GSK announced the submission of a biological license application for SKYCovione to the Korean Ministry of Food and Drug Safety (KMFDS) following positive data obtained in Phase 3 clinical trials. Therefore, the support provided by various government authorities to foster vaccine adjuvant research and development, collaborations between top manufacturers, and innovative product launches through such collaborative business strategies are likely to provide lucrative opportunities for the growth of the vaccine adjuvants market during the forecast period.

The mineral salt adjuvant segment held the largest share of the vaccine adjuvant market by adjuvant class 2022. The market for the emulsion adjuvant segment is anticipated to grow at the fastest CAGR of 14.6% during the forecast period. Mineral salts such as insoluble aluminum salts and calcium phosphates are used as adjuvants in vaccine formulations. Aluminum salt-based adjuvants help induce early and long-lasting protective immunity. Aluminum adjuvants indicated for use in human vaccines are regulated by the US Food and Drug Administration (FDA), and small amounts of aluminum are added to help the body build higher immunogenicity than the antigen alone in the vaccine. Mineral salt adjuvant formulation at the inflammatory site produces a fast immune response by releasing pro-inflammatory cytokines. Therefore, the ability of mineral salt-based adjuvants to induce a fast immune response toward antigens favors the vaccine adjuvants market growth.

In 2022, North America contributed the largest global vaccine adjuvant market share. Asia Pacific is expected to register the highest CAGR during 2022-2030. Accelerated product approvals for vaccine adjuvants bolster market growth in North America. Additionally, the presence of top manufacturers producing adjuvants further enhances the overall market growth.

Fast product approval processes benefit the vaccine adjuvants market in the US. In May 2023, GlaxoSmithKline (GSK) won US Food and Drug Administration (FDA) approval for its Arexvy (respiratory syncytial virus vaccine, adjuvanted) vaccine intended for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV). Thus, Arexvy became the world's first FDA-approved RSV vaccine for older adults. In October 2022, Novavax, Inc. received an Emergency Use Authorization (EUA) from the FDA for its COVID-19 adjuvanted vaccine, indicated as a booster for adult patients.

Industry Developments and Future Opportunities:

Various strategic developments by leading players operating in the vaccine adjuvant market are listed below:

In April 2022, GSK plc and SK Bioscience submitted a biologics license application for SKYCovione, a recombinant protein-based, adjuvanted COVID-19 vaccine candidate. It contains GSK's pandemic adjuvant. The companies have submitted a biologics license application to the Korean Ministry of Food and Drug Safety following the positive data obtained in Phase III clinical trials.

In November 2021, Seppic launched MONTANIDE GEL P PR, an aqueous adjuvant based on a polymeric technology exclusively dedicated to avian injectable vaccines, meeting the need for innocuity in the avian market. In addition, MONTANIDE GEL P PR is particularly stable and can resist destabilizing antigenic media frequently used in avian vaccines.

In October 2023, SPI Pharma Inc. and Q-Vant Biosciences Inc. announced a partnership that combines Q-Vant's leadership in sustainable saponin extraction technology with SPI's global reach and servicing expertise in the pharmaceutical industry. The arrangement includes investment in expanding Q-Vant's proprietary 100% sustainable Q-SAP technology and an exclusive commercial agreement to accelerate the global adoption of their saponin adjuvants for veterinary and human vaccine formulations.

In January 2023, the Korean Ministry of Food and Drug Safety (KMFDS) granted SK Bioscience enhanced manufacturing and marketing authorization for NuvaxovidTM to be administered to adults aged 18 and above as a booster.

Reasons to Buy:

  • Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the vaccine adjuvants market.
  • Highlights key business priorities in order to assist companies to realign their business strategies.
  • The key findings and recommendations highlight crucial progressive industry trends in the global vaccine adjuvants market, thereby allowing players across the value chain to develop effective long-term strategies.
  • Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
  • Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.
  • Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.

Table Of Contents

1. Introduction

  • 1.1 The Insight Partners Research Report Guidance
  • 1.2 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights

3. Research Methodology

  • 3.1 Coverage
  • 3.2 Secondary Research
  • 3.3 Primary Research

4. Vaccine Adjuvants Market Landscape

  • 4.1 PEST Analysis

5. Vaccine Adjuvants Market - Key Market Dynamics

  • 5.1 Vaccine Adjuvants Market - Key Market Dynamics
  • 5.2 Market Drivers
    • 5.2.1 Rising Number of Infectious Disease Outbreaks and Pandemic
    • 5.2.2 Approvals of Veterinary Vaccine Adjuvants
  • 5.3 Market Restraints
    • 5.3.1 Product Recalls and Adverse Effects
  • 5.4 Market Opportunity
    • 5.4.1 Support for Developments in Adjuvant Studies and Collaborative Efforts for Product Launches
  • 5.5 Future Trends
    • 5.5.1 Technological Advancements
  • 5.6 Impact of Drivers and Restraints:

6. Vaccine Adjuvants Market - Global Market Analysis

  • 6.1 Vaccine Adjuvants Market Revenue (US$ Million), 2022-2030
    • 6.1.1 Overview
  • 6.2 Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)

7. Vaccine Adjuvants Market Analysis - by Adjuvant Class

  • 7.1 Overview
  • 7.2 Mineral Salt Adjuvant
    • 7.2.1 Overview
    • 7.2.2 Mineral Salt Adjuvant: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.3 Emulsion Adjuvant
    • 7.3.1 Overview
    • 7.3.2 Emulsion Adjuvant: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.4 Liposome Adjuvant
    • 7.4.1 Overview
    • 7.4.2 Liposome Adjuvant: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.5 Others
    • 7.5.1 Overview
    • 7.5.2 Others: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)

8. Vaccine Adjuvants Market Analysis - by Type

  • 8.1 Human Vaccine Adjuvant
    • 8.1.1 Overview
    • 8.1.2 Human Vaccine Adjuvant: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
  • 8.2 Veterinary Vaccine Adjuvant
    • 8.2.1 Overview
    • 8.2.2 Veterinary Vaccine Adjuvant: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)

9. Vaccine Adjuvants Market - Geographical Analysis

  • 9.1 North America
    • 9.1.1 North America Vaccine Adjuvants Market Overview
    • 9.1.2 North America: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
      • 9.1.2.1 North America: Vaccine Adjuvants Market - Revenue and Forecast Analysis - by Adjuvant Class
      • 9.1.2.2 North America: Vaccine Adjuvants Market - Revenue and Forecast Analysis - by Type
    • 9.1.3 North America: Vaccine Adjuvants Market - Revenue and Forecast Analysis - by Country
      • 9.1.3.1 United States: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 9.1.3.1.1 Overview
        • 9.1.3.1.2 United States: Glucose Monitoring Devices Market - Revenue and Forecast to 2030 (US$ Million)
        • 9.1.3.1.3 United States: Vaccine Adjuvants Market Breakdown, by Adjuvant Class
        • 9.1.3.1.4 United States: Vaccine Adjuvants Market Breakdown, by Type
      • 9.1.3.2 Canada: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 9.1.3.2.1 Overview
        • 9.1.3.2.2 Canada: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 9.1.3.2.3 Canada: Vaccine Adjuvants Market Breakdown, by Adjuvant Class
        • 9.1.3.2.4 Canada: Vaccine Adjuvants Market Breakdown, by Type
      • 9.1.3.3 Mexico: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 9.1.3.3.1 Overview
        • 9.1.3.3.2 Mexico: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 9.1.3.3.3 Mexico: Vaccine Adjuvants Market Breakdown, by Adjuvant Class
        • 9.1.3.3.4 Mexico: Vaccine Adjuvants Market Breakdown, by Type
  • 9.2 Europe
    • 9.2.1 Europe Vaccine Adjuvants Market Overview
    • 9.2.2 Europe: Vaccine Adjuvants Market Revenue and Forecast to 2030 (US$ Million)
      • 9.2.2.1 Europe: Vaccine Adjuvants Market - Revenue and Forecast Analysis - by Adjuvant Class
      • 9.2.2.2 Europe: Vaccine Adjuvants Market - Revenue and Forecast Analysis - by Type
    • 9.2.3 Europe: Vaccine Adjuvants Market
      • 9.2.3.1 Germany: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 9.2.3.1.1 Overview
        • 9.2.3.1.2 Germany: Glucose Monitoring Devices Market - Revenue and Forecast to 2030 (US$ Million)
        • 9.2.3.1.3 Germany: Vaccine Adjuvants Market Breakdown, by Adjuvant Class
        • 9.2.3.1.4 Germany: Vaccine Adjuvants Market Breakdown, by Type
      • 9.2.3.2 United Kingdom: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 9.2.3.2.1 Overview
        • 9.2.3.2.2 United Kingdom: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 9.2.3.2.3 United Kingdom: Vaccine Adjuvants Market Breakdown, by Adjuvant Class
        • 9.2.3.2.4 United Kingdom: Vaccine Adjuvants Market Breakdown, by Type
      • 9.2.3.3 France: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 9.2.3.3.1 Overview
        • 9.2.3.3.2 France: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 9.2.3.3.3 France: Vaccine Adjuvants Market Breakdown, by Adjuvant Class
        • 9.2.3.3.4 France: Vaccine Adjuvants Market Breakdown, by Type
      • 9.2.3.4 Italy: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 9.2.3.4.1 Overview
        • 9.2.3.4.2 Italy: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 9.2.3.4.3 Italy: Vaccine Adjuvants Market Breakdown, by Adjuvant Class
        • 9.2.3.4.4 Italy: Vaccine Adjuvants Market Breakdown, by Type
      • 9.2.3.5 Spain: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 9.2.3.5.1 Overview
        • 9.2.3.5.2 Spain: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 9.2.3.5.3 Spain: Vaccine Adjuvants Market Breakdown, by Adjuvant Class
        • 9.2.3.5.4 Spain: Vaccine Adjuvants Market Breakdown, by Type
      • 9.2.3.6 Rest of Europe: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 9.2.3.6.1 Overview
        • 9.2.3.6.2 Rest of Europe: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 9.2.3.6.3 Rest of Europe: Vaccine Adjuvants Market Breakdown, by Adjuvant Class
        • 9.2.3.6.4 Rest of Europe: Vaccine Adjuvants Market Breakdown, by Type
  • 9.3 Asia Pacific
    • 9.3.1 Asia Pacific Vaccine Adjuvants Market Overview
    • 9.3.2 Asia Pacific: Vaccine Adjuvants Market
      • 9.3.2.1 Asia Pacific: Vaccine Adjuvants Market - Revenue and Forecast Analysis - by Adjuvant Class
    • 9.3.3 Asia Pacific: Vaccine Adjuvants Market
      • 9.3.3.1 Asia Pacific: Vaccine Adjuvants Market - Revenue and Forecast Analysis - by Type
    • 9.3.4 Asia Pacific: Vaccine Adjuvants Market - Revenue and Forecast Analysis - by Country
      • 9.3.4.1 China: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 9.3.4.1.1 Overview
        • 9.3.4.1.2 China: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 9.3.4.1.3 China: Vaccine Adjuvants Market Breakdown, by Adjuvant Class
        • 9.3.4.1.4 China: Vaccine Adjuvants Market Breakdown, by Type
      • 9.3.4.2 Japan: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 9.3.4.2.1 Overview
        • 9.3.4.2.2 Japan: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 9.3.4.2.3 Japan: Vaccine Adjuvants Market Breakdown, by Adjuvant Class
        • 9.3.4.2.4 Japan: Vaccine Adjuvants Market Breakdown, by Type
      • 9.3.4.3 India: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 9.3.4.3.1 Overview
        • 9.3.4.3.2 India: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 9.3.4.3.3 India: Vaccine Adjuvants Market Breakdown, by Adjuvant Class
        • 9.3.4.3.4 India: Vaccine Adjuvants Market Breakdown, by Type
      • 9.3.4.4 Australia: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 9.3.4.4.1 Overview
        • 9.3.4.4.2 Australia: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 9.3.4.4.3 Australia: Vaccine Adjuvants Market Breakdown, by Adjuvant Class
        • 9.3.4.4.4 Australia: Vaccine Adjuvants Market Breakdown, by Type
      • 9.3.4.5 South Korea: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 9.3.4.5.1 Overview
        • 9.3.4.5.2 South Korea: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 9.3.4.5.3 South Korea: Vaccine Adjuvants Market Breakdown, by Adjuvant Class
        • 9.3.4.5.4 South Korea: Vaccine Adjuvants Market Breakdown, by Type
      • 9.3.4.6 Rest of APAC: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 9.3.4.6.1 Overview
        • 9.3.4.6.2 Rest of APAC: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 9.3.4.6.3 Rest of APAC: Vaccine Adjuvants Market Breakdown, by Adjuvant Class
        • 9.3.4.6.4 Rest of APAC: Vaccine Adjuvants Market Breakdown, by Type
  • 9.4 Middle East and Africa
    • 9.4.1 Middle East and Africa Vaccine Adjuvants Market Overview
    • 9.4.2 Middle East and Africa: Vaccine Adjuvants Market
      • 9.4.2.1 Middle East and Africa: Vaccine Adjuvants Market - Revenue and Forecast Analysis - by Adjuvant Class
      • 9.4.2.2 Middle East and Africa: Vaccine Adjuvants Market - Revenue and Forecast Analysis - by Type
    • 9.4.3 Middle East and Africa: Vaccine Adjuvants Market - Revenue and Forecast Analysis - by Country
      • 9.4.3.1 Saudi Arabia: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 9.4.3.1.1 Overview
        • 9.4.3.1.2 Saudi Arabia: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 9.4.3.1.3 Saudi Arabia: Vaccine Adjuvants Market Breakdown, by Adjuvant Class
        • 9.4.3.1.4 Saudi Arabia: Vaccine Adjuvants Market Breakdown, by Type
      • 9.4.3.2 South Africa: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 9.4.3.2.1 Overview
        • 9.4.3.2.2 South Africa: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 9.4.3.2.3 South Africa: Vaccine Adjuvants Market Breakdown, by Adjuvant Class
        • 9.4.3.2.4 South Africa: Vaccine Adjuvants Market Breakdown, by Type
      • 9.4.3.3 United Arab Emirates: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 9.4.3.3.1 Overview
        • 9.4.3.3.2 United Arab Emirates: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 9.4.3.3.3 United Arab Emirates: Vaccine Adjuvants Market Breakdown, by Adjuvant Class
        • 9.4.3.3.4 United Arab Emirates: Vaccine Adjuvants Market Breakdown, by Type
      • 9.4.3.4 Rest of Middle East and Africa: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 9.4.3.4.1 Overview
        • 9.4.3.4.2 Rest of Middle East and Africa: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 9.4.3.4.3 Rest of Middle East and Africa: Vaccine Adjuvants Market Breakdown, by Adjuvant Class
        • 9.4.3.4.4 Rest of Middle East and Africa: Vaccine Adjuvants Market Breakdown, by Type
  • 9.5 South and Central America
    • 9.5.1 South and Central America Vaccine Adjuvants Market Overview
    • 9.5.2 South and Central America: Vaccine Adjuvants Market
      • 9.5.2.1 South and Central America: Vaccine Adjuvants Market - Revenue and Forecast Analysis - by Adjuvant Class
    • 9.5.3 South and Central America: Vaccine Adjuvants Market
      • 9.5.3.1 South and Central America: Vaccine Adjuvants Market - Revenue and Forecast Analysis - by Type
    • 9.5.4 South and Central America: Vaccine Adjuvants Market - Revenue and Forecast Analysis - by Country
      • 9.5.4.1 Brazil: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 9.5.4.1.1 Overview
        • 9.5.4.1.2 Brazil: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 9.5.4.1.3 Brazil: Vaccine Adjuvants Market Breakdown, by Adjuvant Class
        • 9.5.4.1.4 Brazil: Vaccine Adjuvants Market Breakdown, by Type
      • 9.5.4.2 Argentina: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 9.5.4.2.1 Overview
        • 9.5.4.2.2 Argentina: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 9.5.4.2.3 Argentina: Vaccine Adjuvants Market Breakdown, by Adjuvant Class
        • 9.5.4.2.4 Argentina: Vaccine Adjuvants Market Breakdown, by Type
      • 9.5.4.3 Rest of South and Central America: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 9.5.4.3.1 Overview
        • 9.5.4.3.2 Rest of South and Central America: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 9.5.4.3.3 Rest of South and Central America: Vaccine Adjuvants Market Breakdown, by Adjuvant Class
        • 9.5.4.3.4 Rest of South and Central America: Vaccine Adjuvants Market Breakdown, by Type

10. Industry Landscape

  • 10.1 Overview
  • 10.2 Growth Strategies in the Global Vaccine Adjuvants Market
  • 10.3 Organic Developments
    • 10.3.1 Overview
  • 10.4 Inorganic Developments
    • 10.4.1 Overview

11. Company Profiles

  • 11.1 SPI Pharma Inc
    • 11.1.1 Key Facts
    • 11.1.2 Business Description
    • 11.1.3 Products and Services
    • 11.1.4 Financial Overview
    • 11.1.5 SWOT Analysis
    • 11.1.6 Key Developments
  • 11.2 GSK Plc
    • 11.2.1 Key Facts
    • 11.2.2 Business Description
    • 11.2.3 Products and Services
    • 11.2.4 Financial Overview
    • 11.2.5 SWOT Analysis
    • 11.2.6 THREATS
    • 11.2.7 Key Developments
  • 11.3 CSL Ltd
    • 11.3.1 Key Facts
    • 11.3.2 Business Description
    • 11.3.3 Products and Services
    • 11.3.4 Financial Overview
    • 11.3.5 SWOT Analysis
    • 11.3.6 Key Developments
  • 11.4 Seppic SA
    • 11.4.1 Key Facts
    • 11.4.2 Business Description
    • 11.4.3 Products and Services
    • 11.4.4 Financial Overview
    • 11.4.5 SWOT Analysis
    • 11.4.6 Key Developments
  • 11.5 Hawaii Biotech Inc
    • 11.5.1 Key Facts
    • 11.5.2 Business Description
    • 11.5.3 Products and Services
    • 11.5.4 Financial Overview
    • 11.5.5 SWOT Analysis
    • 11.5.6 Key Developments
  • 11.6 Dynavax Technologies Corp
    • 11.6.1 Key Facts
    • 11.6.2 Business Description
    • 11.6.3 Products and Services
    • 11.6.4 Financial Overview
    • 11.6.5 SWOT Analysis
    • 11.6.6 Key Developments
  • 11.7 InvivoGen SAS
    • 11.7.1 Key Facts
    • 11.7.2 Business Description
    • 11.7.3 Products and Services
    • 11.7.4 Financial Overview
    • 11.7.5 SWOT Analysis
    • 11.7.6 Key Developments
  • 11.8 Croda International Plc
    • 11.8.1 Key Facts
    • 11.8.2 Business Description
    • 11.8.3 Products and Services
    • 11.8.4 Financial Overview
    • 11.8.5 SWOT Analysis
    • 11.8.6 Key Developments
  • 11.9 Novavax Inc
    • 11.9.1 Key Facts
    • 11.9.2 Business Description
    • 11.9.3 Products and Services
    • 11.9.4 Financial Overview
    • 11.9.5 SWOT Analysis
    • 11.9.6 Key Developments
  • 11.10 Phibro Animal Health Corp
    • 11.10.1 Key Facts
    • 11.10.2 Business Description
    • 11.10.3 Products and Services
    • 11.10.4 Financial Overview
    • 11.10.5 SWOT Analysis
    • 11.10.6 Key Developments

12. Appendix

  • 12.1 About The Insight Partners
  • 12.1 Glossary of Terms